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Summary Rhinocladiella mackenziei (formerly Ramichloridium mackenziei), a
causative agent of cerebral phaeohyphomycosis, is extremely rare and it is geo-
graphically limited to the Middle East. The organism has a predilection to cause
brain infections and results in a grave prognosis with a high mortality rate. The
current patient was admitted to a long term care facility with chronic respira-
tory failure and dependence on a mechanical ventilator. She later developed left
sided weakness and a CT-scan of the brain revealed multiple variable sized hypo-
dense, well-deﬁned lesions with ring enhancement. A stereotactic needle aspiration
of the largest lesion showed fungal hyphae. The ﬁnal culture grew R. mackenzie.
The patient was initially started on liposomal amphotericin B, then voriconazole and
caspofungin intravenously as posaconazole was not available. The patient failed to
respond to antifungal therapy and ﬁnally she died 34 days after the start of the
treatment. R. mackenziei is a highly virulent agent, and should be considered in the
differential diagnosis of central nervous system disease in patients from the Middle
East.
© 2011 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.∗ Corresponding author at: P.O. Box 76, Room A-428-2, Building
61, Dhahran Health Center, Saudi Aramco, Dhahran 31311,
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erebral phaeohyphomycosis is an infection caused
y dematiaceous fungi especially in immuno-
ompromized patients [1—3]. Of the dematia-
eous fungi known to be neurotrophic include
ladophialophora bantiana,Wangiella dermatitidis
Sciences. Published by Elsevier Ltd. All rights reserved.
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verebral phaeohyphomycosis due to Rhinocladiella
nd Chaetomium atrobrunneum [4—7]. In addition,
hinocladiella mackenziei (formerly Ramichlorid-
um mackenziei) has been reported to be a
ausative agent of fatal cases of R. mackenziei
nfection [1—3]. R. mackenziei infection appears to
ccur predominantly in the Middle East and to tar-
et the brain exclusively [1—3]. However, it should
e noted that R. mackenziei has not been recovered
rom any environmental source [3]. Recently, two
ases were reported from areas outside of the Mid-
le East, mainly from India and Afghanistan [8,9].
n this report we describe an additional fatal case
f R. mackenziei cerebral infection, and review the
linical characteristics, the treatment and outcome
f this infection.
ase presentation
he patient, a 64 year old Saudi female, was
dmitted initially to a long term care facility
ith chronic respiratory failure and dependence
n the mechanical ventilation. The patient was
nown to have chronic respiratory failure sec-
ndary to chronic obstructive pulmonary disease.
he required hemodialysis multiple times due to
iabetic nephropathy. She remained stable on
echanical ventilation for a few months. Four days
rior to transfer to our hospital, she was noticed
o be sleepy with left sided weakness. There was
o history of fever, chills, nausea or vomiting. A
omputerized axial tomography (CAT) scan of the
rain revealed multiple variable sized hypodence,
ell-deﬁned right parieto-occipital lesions with
ing enhancement. The lesions were surrounded by
oderate vasogenic edema with compression of the
djacent left lateral ventricles (Fig. 1). The patient
as transferred to our institution for further work
p and management.
Past medical history was remarkable for type
diabetes mellitus, diabetic retinopathy and
ephropathy. In addition, she had hyperlipidemia,
ypertension, and congestive heart failure.
Physical examination revealed an elderly female
ith stable vital signs, a temperature of 36.5 ◦C,
lood pressure of 122/75, heart rate of 80/min and
n oxygen saturation of 99%. Chest examination
evealed reduced breath sounds with expiratory
heezing. Examination of the abdomen and the
eart were normal. There was Lower limb edema.
eurologically, she was awake however she did
ot follow verbal commands. She had minimal
ovement of the right limbs to stimulation with
ecreased tendon reﬂexes and no movement in the
ther limbs.
c
t
t
wkenziei (formerly Ramichloridium mackenziei) 97
The magnetic resonance imaging (MRI) of the
rain showed multiple variable sized hetero-
eneous hyperintense predominantly T2 lesions
ocalized to the deep right posterior frontal and
arieto-occipital lobes. The largest lesion mea-
ured 5.0× 4.1× 4.3 cm’s (Fig. 2). There was
assive bilateral paranchymal vasogenic edema
ut involved the right hemisphere more than left
emisphere.
The patient underwent a stereotactic needle
spiration of the largest lesion in the right parieto-
ccipital area. The gram stain showed fungal
yphae. Patient was initially started on liposomal
mphotericin B, however the antifungal medica-
ion was changed to voriconazole and caspofungin
ntravenously as posaconazole was not available.
repeat CT of brain, 18 days after initiation of
he treatment, revealed worsening massive vaso-
enic edema involving the right tempor-parietal
obe right thalamus, and crosses the posterior cor-
us callosum to the contralateral side. Due to the
everity of the illness, the patient continued to
eteriorate and she died 34 days after the start of
he treatment.
ycological ﬁndings
mears of the aspirated brain abscess were stained
ith both Gram stain and hematoxylin and eosin
tains. The smears revealed acute inﬂammatory
xudate admixed with numerous neutrophils. In
ddition, many fungal septate hyphae were seen
Fig. 3). The aspirate was inoculated at 25 ◦C on
lant tubes of Sabouraud’s glucose agar and myco-
ogical agar media. After 22 days, ﬂuffy brown
o dark olive green colonies with raised edges at
he periphery appeared. The isolated organism was
ent to the Fungus Testing Laboratory at the Univer-
ity of Texas Health Science Center at San Antonio,
exas (USA). The ﬁnal result was available about 4-
eek after the death of the patient. The organism
as identiﬁed as R. mackenziei. Unfortunately, no
nit-fungal susceptibility testing was done.
iscussion
nfection by R. mackenziei targets the cerebrum
xclusively. A total of 27 cases were reported pre-
iously (Table 1) and here we report an additional
ase. R. mackenziei is thought to be restricted
o the Middle East [17]. It is interesting to note
hat out of the reported cases, 13 (46%) cases
ere from Saudi Arabia. However, R. mackenziei
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Table 1 Summary of cases of cerebral phaeohyphomycosis caused by Rhinocladiella (Ramichloridium) mackenziei.
Reference Country Age
(years)/sex
Underlying
condition
No. of
abscesses
Surgical
drainage
Antifungal therapy Outcome
[10,11] Saudi Arabia 55/F None Multiple Yes AmB, 5-FC, KTZ Died after 6 months
[10,11] Saudi Arabia 80/M None Solitary Yes AmB, 5-FC, KTZ Died after 2 months
[10] Saudi Arabia 70/M Bowel surgery Multiple Yes AmB, 5-FC NA
[10] Israel 60/F NA Solitary Aspirate NA NA
[10] Qatar 55/M Kidney transplant Solitary Aspirate NA Died
[10] Oman 32/F Kidney transplant Solitary Aspirate NA NA
[10] United Arab Emirates NA NA Solitary Aspirate NA Died
[10] Saudi Arabia 75/M None Multiple Aspirate NA Died
[11] Saudi Arabia 60/M None Multiple Yes AmB, 5-FC, KTZ Died after 8 weeks
[12] Saudi Arabia 36/M Hogkin’s disease
in remission
Solitary Yes ITZ Died after 8 months
[13] Kuwait 58/F Renal failure Multiple Aspirate AmB, ITZ Died after 4 weeks
[14] Saudi Arabia 71/M Chronic
myelogenous
leukemia
Solitary Yes AmB, ITZ Died after 10 days
[14] Saudi Arabia 42/M None Solitary Yes AmB, ITZ Died after 2 weeks
[15] Saudi Arabia 67/F Diabetes mellitus Solitary Aspirate AmB Died after 10 days
[15] Saudi Arabia 65/F Hogkin’s disease Solitary Yes AmB Died after 3 weeks
[16] Kuwait 56/M Chronic liver
disease
Solitary Yes AmB Died after 18 days
[3] Saudi Arabia 62/M Renal transplant Solitary Aspirate LAmB, ITZ, 5-FC then Posa Cured
[1] Saudi Arabia 66/F Diabetes mellitus Multiple Aspirate LAmB, VOR Died after 5 weeks
[17] Qatar 59/F Breast cancer on
chemotherapy
Multiple Aspirate LAmB, VOR Died after 64 days
[8] India 50/M Diabetes mellitus Solitary Yes AmB Died after 2 weeks
[9] Afghanistan 80/F None Multiple Aspirate VOR, POSA Died after 7 months
[18] Pakistan 45/M Diabetes Mellitus Multiple Yes AmB, ITZ Died at 1 month
[18] Pakistan 30/M Head Injury Solitary Yes AmB, ITZ Alive at 10 months
[18] Pakistan 45/M None not known Yes AmB, ITZ NA
[18] Pakistan 20/F Trauma Solitary Aspirate AmB, ITZ Alive at 12 months
[18] Pakistan 53/M Liver transplant Solitary Yes AmB Died at 2 months
[18] Pakistan 75/M History of
tuberculosis
Solitary Yes ITZ Alive at 2 months
Current Saudi Arabia 64/F Diabetes mellitus Multiple Aspirate LAmB, then VOR+caspo Died after 34 days
F, female; M, male; NA, not available.
Antifungal therapy; AmB, amphotericin B; 5FC, 5-ﬂourocytocine; ITZ, itraconazole; FLC, ﬂuconazole; VRC, voriconazole; KTZ, ketoconazole; POS, posaconazole; ANIDO, anidulafungin;
MICA, micafungin; CASPO, caspofungin.
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eﬁned right parieto-occipital lesions with ring enhancem
as never been isolated from the environment in
he country [3]. Thus, the natural niche of this
rganism remains unknown. Recently patients with
. mackenziei brain abscesses were reported from
ndia [8] and Afghanistan [9]. The Indian strain (CBS
25089) originated from a humid subtropical cli-
ate and infected a patient who claimed he had
ever traveled outside India [8]. The other patient
lso did not have any travel history to the Middle
a
H
sbrain showing multiple variable sized hypodence, well-
and moderate vasogenic edema.
ast [9]. Additionally, a total of six new cases were
eported from Pakistan [18]. Thus, the cases do not
eem to be restricted to the Middle East as it was
hought previously.
Most of the patients (60.7%) with R. macken-
iei brain abscess presented with solitary brain
bscesses and the remaining had multiple lesions.
owever, the current patient had multiple lesions
imilar to the remaining (39.3%) of the cases.
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Figure 2 Magnetic resonance imaging (MRI) of the brain
showing multiple variable sized heterogeneous hyperin-
tense predominantly T2 lesions localized to the deep
right posterior frontal and parieto-occipital lobes.
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stain showing many fungal septate hyphae.
This infection has affected apparently immuno-
competent and immunocompromised patients, with
similarly dismal outcomes. Of the total reported
cases, seven (25%) had no reported underlying
conditions [9—11,14,18], ﬁve (18%) patients had
diabetes mellitus [1,8,15,18] and four patients had
solid organ transplant [3,10,18] (Table 1). The cur-
rent patient had diabetes mellitus, a condition that
is found in 18% of the reported cases.
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Surgical drainage was done in 53% of patients,
nd the remaining patients had aspiration only
Table 1). The current patient did not have surgi-
al resection since she had multiple brain lesions.
owever, surgical resection does not seem to
ave major impact on survival. Of the reported
ases, mortality rate was comparable in those who
nderwent surgical resection (84.5%) and those
ho did not have surgical resection (82%). The
utcome may be difﬁcult to ascertain since the
atients received different anti-fungal therapies.
he most commonly used antifungal agent was
mphotericin B (71.4%) alone or in combination
Table 1). In a murine model of R. mackenziei
erebral phaeohyphomycosis, posaconazole was
uperior to amphotericin B and itraconazole and
educed the brain fungal burden [19]. We previ-
usly used posaconazole in the treatment of R.
ackenziei brain abscess and showed a prolonged
urvival of 4 years [3]. However, posaconazole was
ecently tried in one patient but the patient died
ithin 7 months of therapy [9]. Unfortunately,
here was no antifungal sensitivity testing done for
he current isolate. However, a summary of the
vailable data for in vitro antifungal susceptibility
esting for eight strains of R. mackenziei is shown in
able 2. Amphotericin B susceptibility seems to be
train-dependent and the MICs for ﬂuconazole and
-ﬂucytosine were high [17]. On the other hand,
he MIC values against itraconazole, voriconazole,
osaconazole and isavuconazole is difﬁcult to inter-
ret [17]. It seems also that there is no correlation
etween in vitro results and in vivo response in the
ase of the azoles [17]. This is thought to be due
o pharmacokinetics of the drug, combined with
ost factors. An open label clinical trial of the efﬁ-
acy of posaconazole in the treatment of patients
ith CNS fungal infections showed that posacona-
ole was successful in 48% (14 of 29) of the patients
ith cryptococcal infection and in 50% (5 of 10) of
atients infected with other fungal pathogens [20].
owever, posaconazole is not currently approved
or this indication [21]. In addition, the efﬁcacy
f the different antifungal agents in the clinical
ractice against dematiaceous fungi in general and
gainst R. mackenziei is not well documented. The
ortality rate of cerebral phaeohyphomycosis due
o R. mackenziei is associated with a high mortality
ate of 83.3% of all cases with documented out-
ome. However, some of the cases were followed
p for a short duration of less than a year [18]. The
atient in the current report died within 1 month
f the diagnosis. This ﬁnding is slightly less than the
verage survival rate of about 2 months after the
iagnosis (Table 1).
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Table 2 Antifungal susceptibility testing results (MIC g/ml) for Rhinocladiella mackenziei in different studies.
Reference AmB 5-FC ITZ FLC VOR KTZ POS ANIDO MICA CASPO Isavuconazole
[1] 0.3 4 <0.015 <0.015 <0.015
[3] 1 16 <0.015 <0.015
[8] 16 0.063 32 0.5 0.031 4 8 0.5
[12] 1 8 ≤0.015 16
[16] >32 16 0.125 32 0.5 0.25
[17] 16 ≤0.03 ≤0.03 ≤0.03 4 1 1
[19] >16 <0.015 32 0.25
[19] 1 <0.015 16 0.03
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ketoconazole; POS, posaconazole; ANIDO, anidulafungin; MICA
In conclusion, R.mackenziei infection of the cen-
ral nervous system is a challenging disease with a
igh mortality rate. Successful therapy of this seri-
us infection does not seem to be related to surgical
ntervention and the available therapy. The optimal
ntifungal agent is not yet identiﬁed. Patients with
his disease may also need prolonged suppressive
ntifungal therapy.
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